Search the Community
Showing results for tags 'lupus treatments'.
-
Baseline use of hydroxychloroquine (HCQ) in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19. These efficacy data establish that patients with lupus on baseline therapy with HCQ are not universally protected from COVID-19. BMJ Journals, Ann rheumatologist Dis, 05/07/2020. (Also see Treatments for Lupus) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
-
Successful treatment with hydroxychloroquine for systemic lupus erythematosus with cutaneous involvement accompanied by a xanthomatous reaction. As yet unrecognized factors may play a role in the development of a xanthomatous reaction in discoid lupus erythematosus. PubMed, Lupus, 2019 Dec 1:961203319890677. (Also see Treatments for Lupus) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
-
Belimumab alters transitional B-cell subset proportions in patients with stable systemic lupus erythematosus. We show that Belimumab-mediated B-cell activating factor depletion reduces the Transitional 2 subset in patients. PubMed, Lupus, 2019 Oct;28(11):1337-1343. (Also see Treatments for Lupus and Clinical Trials) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
-
- belimumab
- lupus treatments
-
(and 1 more)
Tagged with:
-
Early–stage predictors for treatment responses in patients with active lupus nephritis (LN). The change percentage of urinary protein-to-creatinine ratio >59% and the serum albumin >32.9g/l at the third month were valuable for predicting remission at the sixth month in LN. PubMed, Lupus. 2019 Mar;28(3):283-289. (Also see Treatments for Lupus) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.